Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Case-controlJournal of thrombosis and haemostasis : JTH· Jul 2026

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Asbjørn L Onsaker, Astrid van Hylckama Vlieg, Thor Ueland … Vânia M Morelli

Read paper

Venous ThromboembolismCase-controlQ1IF 4.0

Higher plasma adiponectin levels associated with lower risk of first venous thromboembolism

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Asbjørn L Onsaker … Vânia M Morelli

Journal of thrombosis and haemostasis · Jul 2026 · Q1 in General Medicine

Background

Adiponectin, a hormone-like protein primarily secreted by adipocytes, is typically decreased in obesity.

Purpose

To investigate the association between plasma adiponectin levels and risk of future first lifetime VTE.

Methods

A population-based nested case-control study, including 381 VTE cases and 772 age-and sex-matched controls, was derived from the Tromsø4 survey (1994/95-2007).

n = 381 VTE cases and 772 age-and

Results

high adiponectin, lower future clot risk

OR 0.69 (95% CI 0.48 to 0.99)

null 1

0.48

0.99

CI excludes the null - significant

More results

Q1 (reference) in age- and sex-adjusted analysis for the entire study period.

Q1.

The additional adjustment for body mass index and C-reactive protein had minor impact on risk estimates.

“

Conclusion

Our results suggest that high plasma adiponectin levels are associated with decreased risk of future first lifetime VTE, particularly shortly after cohort inclusion, and that adiponectin might play a role in the pathogenesis of VTE.

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Plasma levels of adiponectin and risk of future incident venous thromboembolism.

Related papers